Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by jicoopon Feb 05, 2019 3:08pm
89 Views
Post# 29322179

RE:Feb. 2019 Version of the Corporate Power Point Presentation

RE:Feb. 2019 Version of the Corporate Power Point PresentationPP Points of note for me :

Estimates for Bladder Cancer: United States: Approximately 81,190 new cases of bladder cancer annually 14 Canada: Approximately 8,900 new cases of bladder cancer annually 15 Europe: Approximately 151,000 new cases of bladder cancer annually 16 Total (Canada, United States and Europe): Approximately 241,090 new cases of bladder cancer annually

Target Market Potential Population Size (Canada, United States and Europe) = 241,090 x 70% x 30% x 50% = 25,314 patients with BCGUnresponsive NMIBC annually, who are unfit for cystectomy or desire bladder-preserving therapies

Target Market Potential is estimated between $1.1 billion to $USD 2.53 billion annually

BIG NUMBERS DOWN THE ROAD if we can get there :

Also, Penile discomfort was covered for all 6 patients, so assume all were Male . Not sure if this was mentioned previously.

Bullboard Posts